Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3790/7/23: Ex-employee v Moderna (preprint data in presentations) β€” No breach

Anonymous ex-employee alleged Moderna misused preprint vaccine effectiveness data, cherry-picked graphs and sought UK contract advantage via JCVI…

8 Mar 2026

Eli Lilly: Sponsored breast cancer editorial promoted via Facebook/Instagram ads reached the public (Clause 26) and lacked clear sponsorship at the outset

A medical publisher’s β€œSponsored” Facebook ad linked to a Lilly-funded breast cancer article. The Panel found disguised promotion,…

8 Mar 2026

AUTH/2131/6/08: Community pharmacist v GrΓΌnenthal Ltd – promotion of Versatis and use of interim comparative data

A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The…

8 Mar 2026

GSK and Roche: Bonviva β€˜Building Bones’ ad reappeared in Pulse, breaching an undertaking (AUTH/2049/9/07 & AUTH/2050/9/07)

GSK and Roche withdrew Bonviva β€˜Building Bones’ materials after an undertaking, but Pulse republished the old ad. Panel…

8 Mar 2026

Flynn Pharma: Actiq β€œturn it on… and off” strapline ruled misleading (AUTH/2303/3/10)

Actiq ad and leavepiece implied breakthrough cancer pain control could be switched β€œon” and β€œoff” like an appliance.…

8 Mar 2026

AUTH/3186/5/19: Anonymous v Almirall β€” Berlin psoriasis meeting arrangements (no breach)

Anonymous ex-employee alleged UK doctors were invited to a β€œlavish” Berlin meeting based on prescribing and that hospitality/entertainment…

8 Mar 2026

AUTH/2398/4/11: Director/Shire v Norgine – Movicol Paediatric Plain β€˜NICE recommends… FIRST-LINE’ campaign (No breach)

Shire challenged Norgine’s β€˜NICE recommends MOVICOL Paediatric Plain FIRST-LINE’ ad/leavepiece as unauthorised, unreferenced and implying off-label paediatric use.…

8 Mar 2026

AUTH/3119/11/18: Director v Pfizer β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3119/11/18 (Director v Pfizer) about clinical trial disclosure. The matter was ruled outwith the scope of…

8 Mar 2026

Boehringer Ingelheim & Lilly: Trajenta β€œControl and care matter” leavepiece – no breach (AUTH/2449/11/11, AUTH/2450/11/11)

A GP alleged Trajenta β€œwith a difference” claims were misleading vs other DPP-4 inhibitors (dose adjustment, renal monitoring,…

8 Mar 2026

Leo Pharma: Picato β€˜Dear Dr’ template letter pad alleged to bypass non-formulary status (AUTH/2633/8/13) – No breach

A pharmacist alleged Leo’s pre-printed β€˜Dear Dr’ forms for Picato were used to bypass local formulary status. PMCPA…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training